Selected Publications

Middleton MR, Lunn JM, Morris C, Rustin G, Wedge SR, Brampton MH, Lind MJ, Lee SM, Newell DR, Bleehen NM, Newlands ES, Calvert AH, Margison GP and Thatcher N. O6-methylguanine-DNA methyltransferase in pre-treatment tumour biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer. 1998; 78: 1199-1202.

Middleton MR, Kelly J, Goodger S, Thatcher N and Margison GP. Four-hourly scheduling of temozolomide improves tumour growth delay but not therapeutic index in A375M melanoma xenografts. Cancer Chemother Pharmacol. 2000; 45: 15-20.

Middleton MR, Kelly J, Thatcher N, Donnelly DJ, McElhinney RS, McMurry TBH, McCormick JE and Margison GP. O6-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts. Int J Cancer 2000; 85: 248-252.

Middleton MR, Lee SM, Arance A, Wood M, Thatcher N and Margison GP. O6-methylguanine formation, repair protein depletion and clinical outcome with a 4-hourly schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study Int J Cancer 2000; 88: 469-473.

Middleton MR, Thatcher N, McMurry T B H, McElhinney R S, Donnelly D J, Margison G P. Effect of 06-(4-Bromothenyl) guanine on different temozolomide schedules in a human melanoma xenograft model. Int J Cancer 2002; 100: 615-617.